VEGFC Protein (AA 103-227)

Catalog No. ABIN2666942

This Recombinant VEGFC protein is expressed in CHO Cells.

Quick Overview for VEGFC Protein (AA 103-227) (ABIN2666942)

Target: VEGFC (Vascular Endothelial Growth Factor C (VEGFC))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: CHO Cells

Application: Flow Cytometry (FACS), Cytometry by Time of Flight (CyTOF)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 103-227

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 = 100 - 500 ng/ml, corresponding to a specific activity of 0.2 - 1.0 x 104 units/mg, as determined by the dose dependent stimulation of HUVEC cell proliferation.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: VEGFC (Vascular Endothelial Growth Factor C (VEGFC))

Alternative Name: VEGF-C

Background: VEGF-C was initially cloned from human prostatic adenocarcinoma cell line PC-3 and human glioma G61 cell cDNA libraries. VEGF-C belongs to the VEGF family that includes the following members, VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF (placental growth factor). In addition, viral VEGF homologs (collectively called VEGF-E) and snake venom VEGFs such as T.f. (Trimeresurus flavoviridis) and svVEGF (called VEGF-F) have been described. The homologus portions of VEGF-C are ~30 % identical to VEGF165, ~27 % to VEGF-B167, ~25 % to PlGF- 1, and ~22-24 % to PDGF-A and PDGF-B. VEGF-C possesses a C-terminal silk-protein-like structural motif (pattern of spacing cysteine residues) not present in other member of the VEGF family. VEGF-C binds to VEGFR3 that is almost exclusively expressed in lymphatic endothelium in adults, whereas in embryos (mid-gestation) it is expressed on blood vessels and is required for blood vascular remodeling. VEGFR3 is shared by VEGF-C and VEGF-D. VEGF-C is required for sprouting of the first lymphatic vessels from embryonic veins. Also, VEGF-C promotes survival of retinal vascular endothelial cells via VEGFR2. High levels of VEGF-C (in serum) have been associated to dyslipidemia and atherosclerosis. In addition, elevated levels of VEGF-C are increased in the serum of patients with some cancers (primary nonsmall cell lung carcinoma, cervical carcinoma, and gastric cancer among others) and it has been suggested that it is correlated with lymph node metastases and poor prognosis.

Molecular Weight: The 135 amino acid recombinant protein has a predicted molecular mass of approximately 15.4 kDa. The DTT-reduced and non-reduced protein migrate at approximately 23-28 and 20-25 kDa by SDS-PAGE respectively. The N-terminal amino acid is Thr.

Pathways: RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2